A Clinical Study to Evaluate CAD-1883 in ET
Cadence-1 is a clinical trial assessing a novel investigational drug, CAD-1883, as a potential treatment for essential tremor. This study is designed to evaluate the safety, tolerability and efficacy of CAD-1883 administered twice daily by mouth to adult patients with moderate-to-severe essential tremor.
Enrollment is now open at multiple research centers throughout the US. Visit the ClinicalTrials.gov website to learn more about the study and about how to participate.